ClinicalTrials.gg
CompletedNCT05373472Updated Dec 4, 2024

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

A Phase 2 interventional study of COVID-19 mRNA vaccine and Placebo in COVID-19, sponsored by CanSino Biologics Inc.. Completed at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by CanSino Biologics Inc. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.

Enrollment
7th of 12
150 · median 157
Started
2022
with 1 other
Phase 2
3 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
2 of 12
CanSino Biologics Inc.

Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 2, and was the 6th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About mRNA COVID-19 Vaccine

mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA COVID-19 Vaccine in COVID-19, or all of them as a file.
02

Study summary

To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups. Each dose group (150 people) will be divided into 2 age groups (75 each):18 to 59 years old and ≥ 60 years old. The subjects will be randomized into vaccine group or placebo group in a ratio of 2:1. Subjects will complete 2 doses of vaccination on Day 0 and Day 21, in which the low-dose group will received 0.3 ml of the study vaccine or placebo, and the high dose group received 0.5 ml of the study vaccine or placebo.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID
  • mRNA
  • Vaccine
  • Placebo
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years and above with not lower than 18 ;
  2. Volunteers are able and willing to comply with the requirements of the clinical trial protocol, and volunteers or witnesses can sign forms;
  3. Willing to discuss the medical history with the investigator or doctor and allow access to all medical records related to this trial;
  4. Provide 48-hour PCR negative report;
  5. Have not received any other COVID-19 vaccines.

Exclusion criteria

Exclusion Criteria:

  • Criteria for exclusion of the first dose

    1. Other medical or psychiatric conditions, including recent (within the past year) or current presence of suicidal ideation/behavior, or laboratory abnormalities that may increase the risk of participating in the study, or subjects who are not suitable to participate in the study according to the investigator's judgment;
    2. Positive for (HIV);
    3. History of infection or disease history of Middle East Respiratory Syndrome (MERS), SARS or other coronaviruses or related immunizations;
    4. History of serious adverse reactions associated with the vaccine and/or a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine under study;
    5. patients with known or suspected immunodeficiency identified by medical history and/or physical examination;
    6. Bleeding constitution or condition associated with prolonged bleeding which investigators believe that intramuscular injection is ;
    7. Women who test positive for blood pregnancy or are breastfeeding, volunteers or their partners have a pregnancy plan within 12 months;
    8. Severe hypertension and uncontrollable medication (on-site measurement: systolic blood pressure ≥ 160mmHg, diastolic blood pressure ≥ 100mmHg);
    9. Have a serious chronic disease or the condition is in the progression period can not be smoothly controlled, such as diabetes, thyroid disease, etc.;
    10. History of severe myocarditis, pericarditis and other heart diseases;
    11. Plans to receive other vaccines within 28 days before and after receiving the test vaccine;
    12. Those receiving immunosuppressive therapy, including cytotoxic drugs or systemic , such as for cancer or diseases, or who were scheduled to receive treatment throughout the study period. If systemic corticosteroids are used in a short period of time (\< 14 days) for the treatment of acute illness, subjects should not enter this study until at least 28 days after corticosteroid therapy has been discontinued prior to study vaccination. Inhalation/spraying, intra-articular, intraskeletal, or topical (skin or eyes) use of corticosteroids is permitted;
    13. Receiving blood/plasma products or immunoglobulins 60 days prior to study vaccination or plan to receive for the entire study duration;
    14. Engage in other interventional studies within 28 days prior to entering the study and/or during the study's participation;
    15. Participated in other interventional studies of lipid-containing nanoparticles;
    16. Have symptoms of COVID-19 such as respiratory symptoms, fever, cough, shortness of breath, and dyspnea;
    17. Fever, axillary temperature > 37.0 °C.

Second dose exclusion criteria:

  1. Severe allergic reactions occur after the first vaccination;
  2. Serious adverse reactions with causal relationship during the first vaccination;
  3. Those who are newly discovered or newly occurring after the first vaccination do not meet the inclusion criteria of the first dose or meet the exclusion criteria of the first dose, and the investigator shall decide whether to continue to participate in the study;
  4. Other reasons for exclusion that the investigators believe.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Vaccine Group, low dose, 18-59 year-old

    2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21

    Biological: COVID-19 mRNA vaccine

  • Experimental
    Vaccine Group, low dose, 60 year-old and above

    2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21

    Biological: COVID-19 mRNA vaccine

  • Experimental
    Vaccine Group, high dose, 18-59 year-old

    2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21

    Biological: COVID-19 mRNA vaccine

  • Experimental
    Vaccine Group, high dose, 60 year-old and above

    2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21

    Biological: COVID-19 mRNA vaccine

  • Placebo comparator
    Placebo Group, low dose, 18-59 year-old

    2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21

    Biological: Placebo

  • Placebo comparator
    Placebo Group, low dose, 60 year-old and above

    2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21

    Biological: Placebo

  • Placebo comparator
    Placebo Group, high dose, 18-59 year-old

    2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21

    Biological: Placebo

  • Placebo comparator
    Placebo Group, high dose, 60 year-old and above

    2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21

    Biological: Placebo

Interventions

  • 2 doses of vaccine on Day 0 and Day 21

  • BiologicalPlacebo

    2 doses of placebo on Day 0 and Day 21

06

What researchers measure

Primary outcomes

  1. Immunogenicity of wild type neutralizing antibodies

    GMT of wild type neutralizing antibodies

    Time frame: 28 days after complete immunization

  2. Immunogenicity of wild type neutralizing antibodies

    Sero-conversation rate of wild type neutralizing antibodies

    Time frame: 28 days after complete immunization

  3. The incidence of adverse reactions (AR)

    To evaluate the incidence of adverse reactions (AR) in all subjects

    Time frame: Within 14 days of each vaccination

Secondary outcomes

  1. The incidence of adverse reactions (AR)

    To evaluate the incidence of adverse reactions (AR) in all subjects

    Time frame: Within 28 days of complete immunization

  2. The incidence of adverse reactions (AR)

    To evaluate the incidence of adverse reactions (AR) in all subjects

    Time frame: Within 60 minutes of each vaccination

  3. The incidence of SAE, MAE and AESI

    To evaluation the incidence of SAE, MAE, and AESI in all subjects

    Time frame: 12 months after complete vaccination

  4. Immunogenicity of wild type neutralizing antibodies

    Sero-conversation rate of wild type neutralizing antibodies

    Time frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose

  5. Immunogenicity of wild type neutralizing antibodies

    GMT of wild type neutralizing antibodies

    Time frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose

  6. Immunogenicity of wild type neutralizing antibodies

    GMI of wild type neutralizing antibodies

    Time frame: Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose

  7. Immunogenicity of wild type neutralizing antibodies

    GMI of wild type neutralizing antibodies

    Time frame: 28 days after complete immunization

  8. Immunogenicity of anti-S-RBD Ig G antibodies

    Sero-conversation rate of anti-S-RBD Ig G antibodies

    Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  9. Immunogenicity of anti-S-RBD Ig G antibodies

    GMC of anti-S-RBD Ig G antibodies

    Time frame: before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  10. Immunogenicity of anti-S-RBD Ig G antibodies

    GMI of anti-S-RBD Ig G antibodies

    Time frame: before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  11. Cellular immunity

    The response levels and positive rates of IL-2 produced by S protein RBD by ICS in the first 15 subjects in each group

    Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  12. Cellular immunity

    The response levels and positive rates of IL-4 produced by S protein RBD by ICS in the first 15 subjects in each group

    Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  13. Cellular immunity

    The response levels and positive rates of IL-5 produced by S protein RBD by ICS in the first 15 subjects in each group

    Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  14. Cellular immunity

    The response levels and positive rates of IL-17 produced by S protein RBD by ICS in the first 15 subjects in each group

    Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  15. Cellular immunity

    The response levels and positive rates of IFN-γ produced by S protein RBD by ICS in the first 15 subjects in each group

    Time frame: Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination

  16. Changes in laboratory indicators

    Changes in white blood cell count

    Time frame: Before 1st dose and 28 days after second dose

  17. Changes in laboratory indicators

    Changes in neutrophils

    Time frame: Before 1st dose and 28 days after second dose

  18. Changes in laboratory indicators

    Changes in lymphocyte count

    Time frame: Before 1st dose and 28 days after second dose

  19. Changes in laboratory indicators

    Changes in platelet count

    Time frame: Before 1st dose and 28 days after second dose

  20. VOC/VOI serum cross neutralization

    To evaluated the level of VOC/VOI serum cross neutralization results in all subjects.

    Time frame: 28 days after complete immunization

07

Study locations

3 sites
  • Beijing Friendship Hospital
    Beijing, Beijing, China
  • Hebei Petro China Center Hospital
    Langfang, Hebei, China
  • Hunan Provincial Center for Disease Control and Prevention
    Changsha, Hunan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Sep 2022, 2 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 2 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2022
First posted
May 13, 2022
StartActual
Jul 6, 2022
Primary completionActual
Sep 21, 2022
CompletionActual
Sep 21, 2022
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05373472
Responsible party
Sponsor
First posted
May 13, 2022
Start date
Jul 6, 2022
Primary completion
Sep 21, 2022
Completion
Sep 21, 2022
Last update
Dec 4, 2024

Study contacts

Ruihua Dong
principal investigator · Beijing Friendship Hospital
Kexin Zhao
principal investigator · Hebei Petro China Center Hospital
Tao Huang
principal investigator · Hunan Provincial Center for Disease Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion